MyPerioPath® Antibiotic Option

MyPerioPath® results provide guidance to the health care provider regarding the bacterial cause to a patient’s periodontal disease and/or risk of complicating other systemic diseases such as cardiovascular disease¹, diabetes², certain cancers³, brain health⁴, musculoskeletal health⁵, and pregnancy outcomes⁶. The health care provider will consider several modes of therapy to help address the pathogenic bacteria and the following therapy will conduct a post-therapy test to objectively measure the impact of the applied therapy on the bacterial profile.

The MyPerioPath® treatment consideration section of the report provides an overview of possible therapies to be determined by the health care provider. This section is thorough; however, it does not include all therapy options. A health care provided should never feel limited by these considerations as they are just that – “considerations.”

Some health care providers opt to utilize the systemic antibiotic option in addition to mechanical debridement. The systemic antibiotic option printed on the report refers to a resource labeled the MyPerioPath® Antibiotic Options. In most cases, when the pathogenic bacteria exceed the Therapeutic Threshold (bold black lines), an algorithm is applied for selecting the evidence-based recommendation(s). If the bacteria levels do not reach the threshold or the option was omitted intentionally and the provider assesses the patient would benefit from antibiotic therapy, then the health care provider can refer to the MyPerioPath® Antibiotic Options for a possible antibiotic selection consideration.

The below video highlights the MyPerioPath® Antibiotic Option.

References:

1. Meurman JH, Sanz M, Janket SJ. Oral health, atherosclerosis, and cardiovascular disease. Crit Rev Oral Biol Med 2004;15:403-13.
2. Kumar M, Mishra L, Mohanty R, Nayak R. “Diabetes and gum disease: the diabolic duo”. Diabetes Metab Syndr 2014;8:255-8.
3. Jacob JA. Study Links Periodontal Disease Bacteria to Pancreatic Cancer Risk. JAMA 2016;315:2653-4.
4. Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 2019;5:eaau3333.
5. Johansson L, Sherina N, Kharlamova N, et al. Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis. Arthritis Res Ther 2016;18:201.
6. Persson GR, Hitti J, Paul K, et al. Tannerella forsythia and Pseudomonas aeruginosa in subgingival bacterial samples from parous women. J Periodontol 2008;79:508-16.
7. For more information on how to become an OralDNA Provider – scan HERE: 

• Author
• Recent Posts

Diane Larson RDH, BSDH

Diane Larson, RDH, BSDH has over 20 years of dental experience. She is a member of the ADHA/ MnDHA. Although she is no longer providing patient care chair side, her passion is helping clinicians provide a higher quality of care for their patients by assisting in developing an evidence based treatment plan. She considers herself an extension of every team that utilizes OralDNA services. Her total health approach is complimented by her nutritional knowledge. She is from the Midwest and calls Minnesota home, where she lives with her husband.

Latest posts by Diane Larson RDH, BSDH (see all)

• The Winning Team: The Healthcare Provider & The Clinical Laboratory - April 12, 2024
• An Introduction to the History of Clinical Laboratory Testing - October 13, 2023
• AAOSH Hot Topics 2023: Don’t Be Left Out in the Cold—Attend!!! - January 13, 2023